Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.

Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.

Abstract: Disclosed herein are compositions including an inhibitor of extracellular human metallothionein (MT) and a pancreatic targeting moiety linked to the inhibitor of extracellular human MT.

Abstract: Disclosed herein are isolated anti-metallothionein antibodies, or fragments thereof, and their use in treating intestinal inflammation, diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease.

Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.

Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.

Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.

Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.

Abstract: An assay technique for label-free, highly parallel, qualitative and quantitative detection of specific cell populations in a sample and for assessing cell functional status, cell-cell interactions and cellular responses to drugs, environmental toxins, bacteria, viruses and other factors that may affect cell function.

Abstract: Ifenprodil is useful for the treatment of pain.

Abstract: A non-opioid analgesic is used for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic.

Abstract: An assay technique for label-free, highly parallel, qualitative and quantitative detection of specific cell populations in a sample and for assessing cell functional status, cell-cell interactions and cellular responses to drugs, environmental toxins, bacteria, viruses and other factors that may affect cell function.

Abstract: The invention relates to the use of nefopam for the manufacture of a medicament for the treatment of nausea, dizziness, blurred vision and emesis.

Abstract: (+)-Nefopam is formulated for intranasal administration, for use in the treatment of pain.

Abstract: Ifenprodil is useful for the treatment of pain, e.g. on administration intranasally or by another route that avoids first-pass metabolism.

Abstract: The invention provides human lipid-associated molecules (LIPAM) and polynucleotides which identify and encode LIPAM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LIPAM.

Abstract: As disclosed herein, the present invention is directed to a novel system for monitoring cell movement in response to chemotactic and chemokinetic factors. In this system, cells migrate in an under-agarose environment and their position is monitored using a system capable of measuring changes in impedance and other electrical parameters of the system at a target electrode lithographed onto a substrate as the cells arrive at the target. With the disclosed system, the time of arrival of cells at the target electrode is proportional to the dose of the chemoattractant species used to stimulate the cells and can be assessed by changes in resistance at the electrode. The system is readily able to distinguish between wild-type cells and mutants that are deficient in their chemotactic response. In addition, agents that interfere with chemotactic motility can be shown to lead to delayed arrival of cells at the target electrode.

Abstract: Metallothionein is a stress response protein responsible for some forms of stress-related immunosuppression. An anti-metallothionein antibody can stimulate the humoral immune response to T-dependent antigens. An anti-metallothionein antibody is particularly useful when administered with an antigen to stimulate the immune response in a subject. An anti-metallothionein antibody can be administered to a subject with a vaccine to immunize the subject.

Abstract: As disclosed herein, the present invention is directed to a novel system for monitoring cell movement in response to chemotactic and chemokinetic factors. In this system, cells migrate in an under-agarose environment and their position is monitored using a system capable of measuring changes in impedance and other electrical parameters of the system at a target electrode lithographed onto a substrate as the cells arrive at the target. With the disclosed system, the time of arrival of cells at the target electrode is proportional to the dose of the chemoattractant species used to stimulate the cells and can be assessed by changes in resistance at the electrode. The system is readily able to distinguish between wild-type cells and mutants that are deficient in their chemotactic response. In addition, agents that interfere with chemotactic motility can be shown to lead to delayed arrival of cells at the target electrode.

Abstract: An improved biopsy needle having an outer cannula, an inner tube, and a stylet. A snare in the form of a coil is provided between the distal ends of the outer cannula and the inner tube. The coil is coupled to a sleeve affixed to the inner surface of the outer cannula using axially directed coupling elements. Upon rotation of the inner tube with respect to the outer cannula, the coil will decrease in diameter to either sever or hold the biopsy piece within the outer needle. After removal of the needle from the patient, rotating the inner tube in the opposite direction will cause the coil to expand to its original diameter and allow the biopsy piece to be removed from the needle.